Post-marketing surveillance of Levofloxacin 0.5% ophthalmic solution for external ocular infections

Kanda Y., Kayama T., Okamoto S., Hashimoto M., Ishida C., Yanai T., Fukumoto M., Kunihiro E.

2012
Drugs in R and D

View publication

Therapeutic Area

Front of the eye (FOTE)
Categories

Clinical development

Affiliations

Post-Marketing Surveillance Group, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Drug Safety Information Group, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Safety Vigilance Group, Santen Pharmaceutical Co., Ltd., 3-9-19 Shimo-Shinjo, Osaka 533-8651, Japan

Related Publications

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.

Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.

Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.

View all Front of the eye (FOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022